Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 20;11(9):e007366. doi: 10.1136/jitc-2023-007366

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Response of 56 patients with HCC to conversion therapy with lenvatinib and anti-PD-1 antibodies (A and B) Waterfall plot of the best percentage change in target-lesion size from baseline by IIR assessment according to mRECIST (A) and RECIST 1.1 (B). (C) Swimmer plot of overall survival in 56 patients with HCC receiving lenvatinib plus PD-1 inhibitors. BCLC, Barcelona Clinic Liver Cancer; CNLC, China Liver Cancer; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HVTT, hepatic vein tumor thrombosis; IIR, independent imaging review; mRECIST, modified RECIST; NE, not estimable; PD, progressive disease; PD-1, programmed cell death protein-1; PR: partial response; PVTT: portal vein tumor thrombus; RECIST 1.1, Response Evaluation Criteria in Solid Tumors V.1.1.